WO2023018316A1 - Composition cosmétique contenant un inhibiteur d'importation nucléaire capable de pénétrer dans les cellules amélioré pour prévenir le vieillissement de la peau ou réduire les rides de la peau - Google Patents

Composition cosmétique contenant un inhibiteur d'importation nucléaire capable de pénétrer dans les cellules amélioré pour prévenir le vieillissement de la peau ou réduire les rides de la peau Download PDF

Info

Publication number
WO2023018316A1
WO2023018316A1 PCT/KR2022/012186 KR2022012186W WO2023018316A1 WO 2023018316 A1 WO2023018316 A1 WO 2023018316A1 KR 2022012186 W KR2022012186 W KR 2022012186W WO 2023018316 A1 WO2023018316 A1 WO 2023018316A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
cosmetic composition
icp
lotion
peptide
Prior art date
Application number
PCT/KR2022/012186
Other languages
English (en)
Korean (ko)
Inventor
조대웅
Original Assignee
주식회사 셀리버리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 셀리버리 filed Critical 주식회사 셀리버리
Priority to KR1020247000048A priority Critical patent/KR20240019216A/ko
Publication of WO2023018316A1 publication Critical patent/WO2023018316A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals

Definitions

  • the present invention relates to a composition comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide, and more specifically, SEQ ID NO: 1 having an effect of preventing skin aging and improving skin wrinkles. It relates to a cosmetic composition or an external preparation for skin containing as an active ingredient.
  • iCP-NI cell-permeable nuclear import inhibitor
  • the skin is a membrane that covers the outside of the body, and the most important role of the skin is to act as a defense barrier to protect the skin from external bacterial invasion and damage, and at the same time to prevent heat and moisture loss from the inside.
  • Human skin constantly undergoes changes, the most representative of which is the deterioration of skin function and visual beauty caused by aging. Aging of the skin is largely divided into internal aging according to genetic factors and external aging according to external environmental factors such as sunlight. Such external aging causes the formation of wrinkles in the skin, and active oxygen, ultraviolet rays, and reduction in collagen biosynthesis are examples of typical wrinkle formation factors (Danielle, H. W., Ann Intern Med., 75(6), 873-880, 1971; Grove, G. L.
  • Collagen is a major matrix protein produced by fibroblasts of the skin.
  • collagen metabolism is activated by promoting the synthesis of collagen in the skin, the components of the dermal matrix increase, and it is found that there are effects such as wrinkle improvement, elasticity enhancement, and skin strengthening.
  • retinoid, TGF- ⁇ growth factor, betulic acid, chlorella extract, etc. are known, but retinoic acid is unstable and stable due to irritation when applied to the skin.
  • CP-NI cell permeable nuclear import inhibitor
  • cSN50.1 peptide cell permeable nuclear import inhibitor
  • TSDT therapeutic molecule systemic delivery technology
  • An improved cell-permeable nuclear import inhibitor (iCP-NI) peptide was prepared by introducing an advanced macromolecule transduction domain (aMTD), which has excellent biocompatibility and , It was confirmed that it has an effect of increasing collagen production, an effect of inhibiting ROS production, an effect of reducing wrinkles, an effect of improving skin moisture content, an effect of improving epidermal elasticity, and an effect of improving skin density, and completed the present invention.
  • aMTD advanced macromolecule transduction domain
  • the present invention is a cosmetic composition for preventing skin aging and improving skin wrinkles comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 as an active ingredient. is intended to provide iCP-NI peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 as an active ingredient.
  • iCP-NI cell-permeable nuclear import inhibitor
  • the skin aging may be photoaging by UV exposure.
  • the iCP-NI peptide may be contained in a concentration of 0.001 to 20 mM in the cosmetic composition.
  • the formulation of the cosmetic composition is lotion (skin lotion), skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, eye cream, moisture
  • lotion skin lotion
  • skin softener skin toner
  • astringent lotion
  • milk lotion moisture lotion
  • nutrient lotion massage cream
  • nutrient cream eye cream
  • moisture One or more may be selected from the group consisting of cream, hand cream, foundation, essence, nutrient essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cleanser.
  • the present invention also provides an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 as an active ingredient for preventing skin aging and improving skin for primary use. It aims to provide an external preparation.
  • iCP-NI cell-permeable nuclear import inhibitor
  • the formulation of the external preparation may be one or more selected from the group consisting of cream, gel, patch, spray, ointment, warning agent, lotion, liniment, pasta and cataplasma. there is.
  • the skin aging may be photoaging by UV exposure.
  • the present invention also relates to skin aging prevention and skin wrinkles comprising the step of applying an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 to the subject. It aims to provide an improvement method.
  • iCP-NI cell-permeable nuclear import inhibitor
  • the improved cell-permeable nuclear import inhibitor (iCP-NI) peptide according to the present invention exhibits excellent effects in skin care, such as preventing skin aging and improving skin wrinkles, so that it can be used as a cosmetic composition or for external use on the skin. It is expected that it can be used effectively.
  • Figure 1 shows the in-vitro efficacy evaluation results for the biocompatibility of the iCP-NI peptide according to the present invention.
  • Figure 2 shows the in-vitro efficacy evaluation results for collagen production of the iCP-NI peptide according to the present invention.
  • Figure 3 shows the in-vitro efficacy evaluation results for collagen production after UVB stimulation of the iCP-NI peptide according to the present invention.
  • Figure 4 shows the results of quantitative analysis of intracellular reactive oxygen species (ROS) inhibition of the iCP-NI peptide according to the present invention.
  • ROS reactive oxygen species
  • Figure 5 shows the intracellular reactive oxygen species (ROS) inhibition image measurement results of the iCP-NI peptide according to the present invention.
  • a cosmetic composition comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide according to a specific embodiment of the present invention will be described in detail.
  • iCP-NI cell-permeable nuclear import inhibitor
  • the term "include” or “comprise” means to include a specific component (or element) without particular limitation unless otherwise stated throughout this specification, and other components (or elements) may not be construed as precluding the addition of
  • amino acid in its broadest sense includes naturally occurring L ⁇ -amino acids or residues thereof as well as D-amino acids and chemically modified amino acids.
  • amino acids may include mimetics and analogs of the aforementioned amino acids.
  • mimetics and analogues may include functional equivalents.
  • skin refers to a tissue covering the body surface of an animal, and is a concept in the broadest sense including not only the tissue covering the body surface such as the face or body, but also the scalp and hair.
  • skin aging refers to symptoms such as reduced skin elasticity, reduced gloss, wrinkle formation, weakened regenerative power, or severe dryness, which may be caused by the passage of time or external environment.
  • the skin aging may be photoaging.
  • the photoaging refers to a phenomenon in which skin damage occurs, such as reduced elasticity and moisture of the skin and formation of wrinkles, when repeatedly or for a long time exposed to ultraviolet rays of the sun's rays.
  • skin wrinkles refers to skin wrinkles formed on the skin without limitation, which are skin wrinkles caused by intrinsic and external factors, for example, skin wrinkles accompanying skin photoaging caused by ultraviolet ray stimulation.
  • the term “improvement” or “treatment” refers to (a) inhibition of the development (b) alleviation and (c) elimination of a dermatitis disorder in a subject.
  • prevention refers to inhibiting the occurrence of a disease or condition in a subject who has not been diagnosed as having the disease or condition, but is predisposed to the disease or condition.
  • the term "application” means any method of contacting the composition according to the present invention to the skin of an individual by any suitable method, and through this, the composition is absorbed into the skin.
  • the present invention provides a cosmetic composition for preventing skin aging and improving skin wrinkles, comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide composed of amino acids of SEQ ID NO: 1 as an active ingredient. .
  • iCP-NI cell-permeable nuclear import inhibitor
  • Prevention of skin aging refers to an action of suppressing skin aging by photoaging or natural aging, but the skin aging is preferably photoaging by UV exposure. Further, according to another embodiment of the present invention, the skin wrinkles may be caused by photoaging or natural aging, more preferably by photoaging, and more preferably by photoaging by UV exposure, but are not limited thereto.
  • the iCP-NI peptide according to the present invention is preferably contained in a concentration of 0.01 to 10000 ppm in the cosmetic composition, more preferably in a concentration of 0.01 to 1000 ppm, but is not limited thereto. If the concentration of the peptide is less than 0.01 ppm, it is difficult to obtain the desired effect of preventing skin aging and improving skin wrinkles, and if it exceeds 10,000 ppm, there is a problem in that the production economy is poor because a clear increase in the effect does not appear with an increase in the content.
  • the iCP-NI peptide according to the present invention can be prepared by general chemical synthesis, for example, solid-phase peptide synthesis, and a microorganism transformed with a recombinant vector containing a nucleic acid encoding the peptide. After expressing the peptide by culturing, it may be prepared by purification by a conventional method, but is not limited thereto.
  • the cosmetic composition according to the present invention may further contain other ingredients that can give a synergistic effect to the effect of the present invention, preferably within a range that does not impair the effect intended by the present invention.
  • the cosmetic composition of the present invention may include conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances, as well as any other substances known to have anti-aging and anti-wrinkle effects, or A carrier may be included.
  • the cosmetic composition according to the present invention is not particularly limited in its formulation, and may be prepared in any formulation commonly prepared in the art, for example, a solution, suspension, emulsion, paste, gel, cream, It can be formulated into lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like.
  • scalp treatment agents, soaps, hair tonics, shampoos, rinses, hair packs, hair gels, lotions, conditioners, hair oils, mousses, creams, solids, solutions, emulsions, dispersants, micelles, liposomes, ointments It may be prepared in the form of lotion, essence, patch or spray.
  • the formulation of the cosmetic composition is a paste, cream or gel
  • animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide are used as carrier components
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, especially in the case of a spray, additionally chlorofluorohydrocarbon, propane / propellants such as butane or dimethyl ether.
  • a solvent, solubilizing agent or emulsifying agent may be used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate , propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan.
  • a liquid diluent such as water, ethanol or propylene glycol
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester
  • Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanth may be used, and in the case of surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate as carrier components , imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol
  • the iCP-NI peptide of the present invention has excellent biocompatibility, can reduce ROS generation and wrinkles, and increase collagen production, skin moisture content, epidermal elasticity and skin density. Therefore, the iCP-NI peptide of the present invention can be usefully used as an active ingredient of a cosmetic composition for preventing skin aging and improving skin wrinkles.
  • the present invention provides a pharmaceutical composition for preventing skin aging and improving skin wrinkles comprising an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide composed of amino acids of SEQ ID NO: 1 as an active ingredient. do.
  • iCP-NI cell-permeable nuclear import inhibitor
  • the pharmaceutical composition according to the present invention includes dermal, buccal, intravenous, intramuscular, intraarterial, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration, preferably oral or parenteral administration.
  • parenteral administration includes subcutaneous, intradermal, intravenous, intramuscular, intralesional injection or infusion techniques.
  • the pharmaceutical composition according to the present invention may contain one or more active ingredients exhibiting the same or similar functions in addition to the iCP-NI peptide according to the present invention.
  • the composition may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively.
  • Solid preparations for oral administration of the pharmaceutical composition include powders, granules, tablets, capsules, soft capsules, pills, and the like.
  • Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. .
  • Formulations for parenteral administration include powders, granules, tablets, capsules, sterilized aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc., and sterile injection preparations according to conventional methods, respectively. It can be formulated and used in the form of a cream, gel, patch, spray, ointment, warning, lotion, liniment, pasta, or cataplasma. , but is not limited thereto. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.
  • the pharmaceutical composition according to the present invention may further contain adjuvants such as preservatives, stabilizers, hydration agents or emulsification accelerators, salts and/or buffers for osmotic pressure control, and other therapeutically useful substances. It can be formulated according to mixing, granulating or coating methods.
  • the pharmaceutical composition according to the present invention may vary depending on various factors including age, body weight, general health, sex, administration time, route of administration, excretion rate, drug combination, and severity of a specific disease.
  • the pharmaceutical composition according to the present invention is formulated in a unit dose form containing the iCP-NI peptide as an active ingredient, the iCP-NI peptide as an active ingredient in a unit dose of about 0.01 to 1,500 mg It is preferable to contain, and the dosage required for adult treatment is usually in the range of about 1 to 500 mg per day depending on the frequency and strength of administration, but is not limited thereto. A total dose of about 5 to 300 mg per day will usually suffice for a single dose for intramuscular or intravenous administration to adults, although higher daily doses may be desirable in some patients.
  • the composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
  • the present invention comprises the step of treating or administering an improved cell-permeable nuclear import inhibitor (iCP-NI) peptide consisting of the amino acid of SEQ ID NO: 1 in a cosmetically or pharmaceutically effective amount to a subject. It provides a method for preventing skin aging and improving skin wrinkles.
  • iCP-NI cell-permeable nuclear import inhibitor
  • the cosmetically or pharmaceutically effective amount is 0.000001 to 100 mg/kg, preferably 0.001 to 10 mg/kg, but is not limited thereto.
  • the treatment or dose may be adjusted according to the weight, age, sex, health condition, diet, administration period, administration method, removal rate, severity of disease, etc. of a specific patient. Treatment or administration may be administered once a day or divided into several times.
  • the subject is a vertebrate animal, preferably a mammal, more preferably a human or an experimental animal such as a rat, rabbit, guinea pig, hamster, dog, or cat, and most preferably a human It may be, but is not limited thereto.
  • the treatment or administration method may be applied, oral or parenteral administration, and in the case of parenteral administration, intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine intrauterine injection It may be administered by injection, intracerebrovascular injection or intrathoracic injection.
  • the iCP-NI peptide composed of the amino acid sequence of SEQ ID NO: 1 according to the present invention uses an advanced macromolecule transduction domain (aMTD) composed of amino acids of SEQ ID NO: 2 and an NF- ⁇ nuclear localization sequence (NLS) composed of amino acids of SEQ ID NO: 3 was prepared (Table 1).
  • aMTD advanced macromolecule transduction domain
  • NLS NF- ⁇ nuclear localization sequence
  • NHDF cells were inoculated into a 24-well plate at a concentration of 2.0 ⁇ 10 4 cells/well and cultured for 24 hours, followed by iCP-NI peptide samples (diluted with medium to final concentrations of 1, 5, 10, 30, and 50 ⁇ M). ) was exchanged with serum-free FBM and cultured for 24 hours. After incubation, 50 ⁇ l of EZ-Cytox was added per well and further incubated for 1 hour. The cultured medium was transferred to a 96-well plate and absorbance was measured at 450 nm using a VERSA max microplate reader (Molecular devices, LCC., USA). The average absorbance value for each sample group was obtained, and cell viability was investigated by comparing the absorbance value of the control group. As a result, it was confirmed that the iCP-NI peptide according to the present invention was not cytotoxic compared to the control group in the concentration range of 1 to 50 ⁇ M (FIG. 1).
  • NHDF cells were inoculated into a 24-well plate at a concentration of 2.0 ⁇ 10 4 cells/well and cultured for 24 hours, then exchanged with serum-free FBM containing diluted samples for each concentration and cultured for 24 hours. After 24 hours of culture, the supernatant was taken, and the amount of procollagen released in the medium was measured for absorbance at 450 nm using a Procollagen Type I C-peptide (PIP) EIA Kit. The positive control group was compared using L-ascorbic acid (0.001%).
  • the iCP-NI peptide according to the present invention significantly increased the amount of intracellular collagen (PIP) production by about 130 to 150% compared to the control group in a concentration-dependent manner in a concentration range of 1 to 50 ⁇ M (FIG. 2).
  • NHDF cells were inoculated into a 24-well plate at a concentration of 3.0 ⁇ 10 4 cells/well and cultured for 24 hours, then the medium was discarded and washed with phosphate buffered saline (PBS), followed by 500 ⁇ l of phosphate buffered saline. was irradiated with 40 mJ of ultraviolet (UVB) and then the phosphate buffered saline was removed. Thereafter, the samples were exchanged with serum-free FBM containing diluted samples for each concentration and cultured for 24 hours.
  • PBS phosphate buffered saline
  • UVB ultraviolet
  • DCF-DA assay was used to measure intracellular reactive oxygen species (ROS) changes.
  • ROS reactive oxygen species
  • ROS reactive oxygen species
  • DCF-DA assay was used to measure intracellular reactive oxygen species (ROS) changes.
  • HaCaT cells were inoculated in a 24-well plate at 1.0 ⁇ 10 5 cells/well and cultured for 24 hours, and the samples were pretreated for 24 hours at concentrations of 1, 5, and 10 uM, washed with PBS, and then mixed with 150 uM of H 2 O 2 . The concentration was further cultured by treatment for 30 minutes.
  • DCF-DA dichlorofluorescein diacetate
  • a dye for measuring intracellular ROS incubating for 30 minutes, washing with PBS, the degree of fluorescence expression was measured and images were displayed using the EVOSTM FL Imaging System.
  • FIG. 6 it was confirmed that the iCP-NI peptide according to the present invention inhibited ROS production in a concentration-dependent manner (FIG. 6).
  • a cream containing the iCP-NI peptide of the present invention as an active ingredient was prepared as shown in Table 2 below (content: parts by weight).
  • a human application test was conducted on 20 test subjects. After washing the cheeks of the face, wait for more than 30 minutes under constant temperature and humidity (22 ⁇ 2°C, 50 ⁇ 5%) conditions to sufficiently stabilize the skin before participating in the test.
  • the wrinkle improvement effect, skin moisture content improvement effect, epidermal elasticity improvement effect, and skin density improvement effect according to the test product before and after use were evaluated according to the following method.
  • the indentation index (Indentation index, Wrinkles: small, A.U.) was measured using Antera 3D.
  • the cosmetic composition containing the iCP-NI peptide according to the present invention reduced the wrinkle index around the eyes at a statistically significant level (p ⁇ 0.05) compared to before the test.
  • Skin moisture content was measured using Corneometre® before the test, 2 weeks after the test and 4 weeks after the test. As a result, it was confirmed that the cosmetic composition containing the iCP-NI peptide according to the present invention increased the skin moisture content at a statistically significant level (p ⁇ 0.05) compared to before the test.
  • Epidermal elasticity (R7: Ur/Uf in cutometer, 2mm) was measured using a Cutometer®MPA 580 2mm Probe before, 2 weeks and 4 weeks after the test. As a result, it was confirmed that the cosmetic composition containing the iCP-NI peptide according to the present invention increased skin elasticity at a statistically significant level (p ⁇ 0.05) compared to before the test.
  • the improved cell-permeable nuclear transport inhibitor (iCP-NI) peptide according to the present invention has excellent biocompatibility, can reduce ROS generation and wrinkles, and increase collagen production, skin moisture content, epidermal elasticity and skin density. Therefore, the iCP-NI peptide of the present invention can be usefully used as an active ingredient of a cosmetic composition for preventing skin aging and improving skin wrinkles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)

Abstract

La présente invention concerne une composition contenant un peptide inhibiteur amélioré d'importation nucléaire capable de pénétrer dans les cellules (iCP-NI) et, plus spécifiquement, une composition cosmétique ou une préparation cutanée à usage externe, contenant, en tant que principe actif, SEQ ID NO : 1 ayant des effets de prévention du vieillissement de la peau et de réduction des rides de la peau.
PCT/KR2022/012186 2021-08-13 2022-08-16 Composition cosmétique contenant un inhibiteur d'importation nucléaire capable de pénétrer dans les cellules amélioré pour prévenir le vieillissement de la peau ou réduire les rides de la peau WO2023018316A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247000048A KR20240019216A (ko) 2021-08-13 2022-08-16 개선된 세포 투과성 핵 수송 억제제를 포함하는 피부 노화 방지 또는 피부 주름 개선용 화장료 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163232766P 2021-08-13 2021-08-13
US63/232,766 2021-08-13

Publications (1)

Publication Number Publication Date
WO2023018316A1 true WO2023018316A1 (fr) 2023-02-16

Family

ID=85200200

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2022/012186 WO2023018316A1 (fr) 2021-08-13 2022-08-16 Composition cosmétique contenant un inhibiteur d'importation nucléaire capable de pénétrer dans les cellules amélioré pour prévenir le vieillissement de la peau ou réduire les rides de la peau
PCT/KR2022/012185 WO2023018315A1 (fr) 2021-08-13 2022-08-16 Composition cosmétique pour l'hydratation de la peau et l'apaisement de la peau comprenant un inhibiteur d'import nucléaire à perméabilité cellulaire améliorée

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/012185 WO2023018315A1 (fr) 2021-08-13 2022-08-16 Composition cosmétique pour l'hydratation de la peau et l'apaisement de la peau comprenant un inhibiteur d'import nucléaire à perméabilité cellulaire améliorée

Country Status (2)

Country Link
KR (2) KR20240019216A (fr)
WO (2) WO2023018316A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235746A1 (en) * 1994-06-13 2004-11-25 Hawiger Jack J. Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US20140309159A1 (en) * 2013-04-11 2014-10-16 Vanderbilt University Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders
WO2017026779A1 (fr) * 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Protéine recombinée cre à perméabilité cellulaire améliorée (icp-cre) et son utilisation
KR20170031243A (ko) * 2014-08-17 2017-03-20 (주)셀리버리 세포 투과성의 향상을 위한 개선된 거대분자 전달 도메인(aMTD) 서열, 이를 코딩하는 폴리뉴클레오타이드, 이를 포함하는 aMTD의 독특한 특징을 확인하는 방법, 이를 포함하는 aMTD 서열을 개발하는 방법
WO2020056250A1 (fr) * 2018-09-14 2020-03-19 Vanderbilt University Méthodes et compositions pour traiter des maladies de la peau

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235746A1 (en) * 1994-06-13 2004-11-25 Hawiger Jack J. Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US20140309159A1 (en) * 2013-04-11 2014-10-16 Vanderbilt University Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders
KR20170031243A (ko) * 2014-08-17 2017-03-20 (주)셀리버리 세포 투과성의 향상을 위한 개선된 거대분자 전달 도메인(aMTD) 서열, 이를 코딩하는 폴리뉴클레오타이드, 이를 포함하는 aMTD의 독특한 특징을 확인하는 방법, 이를 포함하는 aMTD 서열을 개발하는 방법
WO2017026779A1 (fr) * 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Protéine recombinée cre à perméabilité cellulaire améliorée (icp-cre) et son utilisation
WO2020056250A1 (fr) * 2018-09-14 2020-03-19 Vanderbilt University Méthodes et compositions pour traiter des maladies de la peau

Also Published As

Publication number Publication date
KR20240019215A (ko) 2024-02-14
KR20240019216A (ko) 2024-02-14
WO2023018315A1 (fr) 2023-02-16

Similar Documents

Publication Publication Date Title
AU2008327932B2 (en) Compositions for reducing oxidative stress and uses thereof
JP2003238387A (ja) 目の下のたるみおよびくまを緩和するための皮膚外用剤組成物
WO1996014085A1 (fr) Preparation dermoprotectrice d'usage externe
US20170100320A1 (en) Composition for external use skin preparation, containing thioredoxin
KR20160070731A (ko) 인삼 꽃 추출물을 함유하는 피부 외용제 조성물
WO2020218888A1 (fr) Composition cosmétique pour le blanchiment de la peau contenant de nouvelles lactobacillus rhamnosus lm1011 en tant que principe actif
JPH09255547A (ja) 皮膚外用剤
WO2011053007A2 (fr) Composition pour supprimer le rétrécissement des pores ou la sécrétion de sébum comprenant un extrait de potentilla chinensis
WO2023018316A1 (fr) Composition cosmétique contenant un inhibiteur d'importation nucléaire capable de pénétrer dans les cellules amélioré pour prévenir le vieillissement de la peau ou réduire les rides de la peau
WO2013115456A1 (fr) Aliment, substance cosmétique, ou composition pharmaceutique contenant un extrait supercritique de gingembre et un extrait de résidu de persil japonais fermenté
US6245795B1 (en) Melanogenesis inhibitor, skin cosmetic composition and bath preparation
KR20140055155A (ko) 자외선 등 피부 유해물질로부터 피부를 보호하여 피부 염증 또는 노화를 개선하는 물질 살리드로사이드
JP3278138B2 (ja) 皮膚外用剤
WO2015001891A1 (fr) Composition pour augmenter la production de collagène, pour augmenter la production d'élastine et/ou pour activer la migration des kératinocytes et son utilisation
WO2021145699A1 (fr) Composition pour le traitement de maladies de la peau, comprenant de la colchicine
JP4914029B2 (ja) Ｉｖ型およびｖｉｉ型コラーゲン産生促進剤
WO2020111540A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du vieillissement ou de maladies associées au vieillissement, comprenant un complexe d'anthocyanine-polysaccharide en tant que principe actif
JPH09255546A (ja) 皮膚外用剤
US20050048138A1 (en) Use of Rhodiola crenulata extract via the topical route
WO2014058084A1 (fr) Composition cosmétique contenant un gamma-oligopeptide ou des sels de celui-ci pour l'amélioration des rides
WO2023008768A1 (fr) Composition cosmétique pour l'amélioration de la peau, comprenant une récoflavone ou un sel de celle-ci
WO2024049229A1 (fr) Composition cosmétique pour prévenir ou améliorer des maladies de la peau, comprenant un composé dérivé de morus alba en tant que principe actif
WO2024049226A1 (fr) Composition cosmétique pour prévenir ou atténuer des maladies de la peau, contenant un composé dérivé de tribulus terrestris en tant que principe actif
WO2024010355A1 (fr) Composition antivieillissement contenant un extrait de lie de vin de gosori
WO2017094958A1 (fr) Composition pour améliorer le vieillissement de la peau et les rides, contenant un extrait de mélange de coptis teeta wall. et de trichosanthes kirilowii en tant qu'ingrédient actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22856309

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20247000048

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020247000048

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE